3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
36
Neoplasm Metastasis
8
Ovarian Neoplasms
5
Sarcoma
4
Neoplasms
4
Lymphoma, Non-Hodgkin
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Glioma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Medulloblastoma
2
Lymphoma, Mantle-Cell
2
Lung Neoplasms
2
Liposarcoma
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Interventions
Specimen Handling
4
Fluorouracil
4
Bevacizumab
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Gemcitabine
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
Oxaliplatin
2
Leucovorin
2
IDRX-42
2
Folfox protocol
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
repotrectinib
1
plecanatide
1
pembrolizumab
1
patritumab deruxtecan
1
palbociclib
1
linaclotide
1
isosorbide-5-mononitrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
palbociclib
×
90 days
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled